Matches in SemOpenAlex for { <https://semopenalex.org/work/W2614241014> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2614241014 abstract "20016 Background: Chronic Myeloid Leukemia (CML) is one of the rare pediatric cancers. Imatinib is now the standard of care in adult CML (ACML) with newer compounds being investigated to overcome the burden of Imatinib resistance. Pediatric CML (PCML) has been an area little explored and effective strategies are not yet defined. Although, allogenic hematopoietic stem cell transplantation (HSCT) still remains the gold-standard treatment, the choice of drug in the subset in which HSCT is not a suitable option remains to be determined. Methods: This was a single-institution prospective study conducted from April 2004-March 2006, analyzing and comparing 293 Philadelphia chromosome (PH) positive CML patients in pediatric and adolescent subsets (i.e. age =18 years) not eligible for allogenic HSCT with ACML. After obtaining a written informed consent, a starting dose of 400 mg/m 2 /d Imatinib mesylate was administered in adults, whereas in pediatric and adolescents it was 400 mg/m 2 /d if the body surface area (BSA) was <1 m 2 , or 400 mg/d if BSA was >1m 2 . Results: 27 patients were in the age group =18 years; male to female ratio was 1.07:1. Gender ratio in 266 ACML patients showed a male preponderance (2.5:1). The mean age in ACML was 37.4 years. In pediatric subsets, a trend toward CML in adolescents was observed with mean age 14.85 years. Majority of the patients were in chronic phase (81.5% PCML and 85.7% ACML) with overall 93% patients receiving prior hydroxyurea as a cytoreductive agent. An unusual finding was higher incidence of Hypodiploidy (significance undetermined) and 5 patients had double PH. 80.1% ACML patients achieved complete hematological response, but it was significantly lower (59.3%) in PCML. 39.5% ACML achieved major cytogenetic response which was less than most published western data. Hematologic and non-hematologic toxicities (GI, dermatological etc) were found to be higher in ACML. Low toxicities in PCML were attributed to good tolerance to Imatinib therapy; however a higher dropout rate in pediatric subsets was possibly due to poor social and parental support. Conclusion: We conclude that imatinib mesylate is both safe and efficacious drug for ACML, however further research is warranted in pediatric and adolescent population to establish its efficacy. No significant financial relationships to disclose." @default.
- W2614241014 created "2017-05-26" @default.
- W2614241014 creator A5018125098 @default.
- W2614241014 creator A5020305020 @default.
- W2614241014 creator A5040123248 @default.
- W2614241014 date "2007-06-20" @default.
- W2614241014 modified "2023-10-01" @default.
- W2614241014 title "Comparative study of safety and efficacy of imatinib mesylate therapy in pediatric and adult chronic myeloid leukemia" @default.
- W2614241014 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.20016" @default.
- W2614241014 hasPublicationYear "2007" @default.
- W2614241014 type Work @default.
- W2614241014 sameAs 2614241014 @default.
- W2614241014 citedByCount "0" @default.
- W2614241014 crossrefType "journal-article" @default.
- W2614241014 hasAuthorship W2614241014A5018125098 @default.
- W2614241014 hasAuthorship W2614241014A5020305020 @default.
- W2614241014 hasAuthorship W2614241014A5040123248 @default.
- W2614241014 hasConcept C126322002 @default.
- W2614241014 hasConcept C143998085 @default.
- W2614241014 hasConcept C2776960273 @default.
- W2614241014 hasConcept C2777583451 @default.
- W2614241014 hasConcept C2778461978 @default.
- W2614241014 hasConcept C2778729363 @default.
- W2614241014 hasConcept C2993416501 @default.
- W2614241014 hasConcept C3019892230 @default.
- W2614241014 hasConcept C71924100 @default.
- W2614241014 hasConceptScore W2614241014C126322002 @default.
- W2614241014 hasConceptScore W2614241014C143998085 @default.
- W2614241014 hasConceptScore W2614241014C2776960273 @default.
- W2614241014 hasConceptScore W2614241014C2777583451 @default.
- W2614241014 hasConceptScore W2614241014C2778461978 @default.
- W2614241014 hasConceptScore W2614241014C2778729363 @default.
- W2614241014 hasConceptScore W2614241014C2993416501 @default.
- W2614241014 hasConceptScore W2614241014C3019892230 @default.
- W2614241014 hasConceptScore W2614241014C71924100 @default.
- W2614241014 hasLocation W26142410141 @default.
- W2614241014 hasOpenAccess W2614241014 @default.
- W2614241014 hasPrimaryLocation W26142410141 @default.
- W2614241014 hasRelatedWork W1970420999 @default.
- W2614241014 hasRelatedWork W1980928536 @default.
- W2614241014 hasRelatedWork W2019199342 @default.
- W2614241014 hasRelatedWork W2027412286 @default.
- W2614241014 hasRelatedWork W2046012038 @default.
- W2614241014 hasRelatedWork W2346587074 @default.
- W2614241014 hasRelatedWork W2396472562 @default.
- W2614241014 hasRelatedWork W2409053948 @default.
- W2614241014 hasRelatedWork W2415374392 @default.
- W2614241014 hasRelatedWork W2187195062 @default.
- W2614241014 isParatext "false" @default.
- W2614241014 isRetracted "false" @default.
- W2614241014 magId "2614241014" @default.
- W2614241014 workType "article" @default.